Lorenzo Fuccio, MD; Rocco Maurizio Zagari, MD; Franco Bazzoli, MD
Potential Financial Conflicts of Interest: None disclosed.
Fuccio L, Zagari RM, Bazzoli F. Could Increasing the Duration of Triple Therapy Be a Clinically Useful Strategy?. Ann Intern Med. 2008;148:624-625. doi: 10.7326/0003-4819-148-8-200804150-00010
Download citation file:
Published: Ann Intern Med. 2008;148(8):624-625.
We appreciate the comments of Dr. Calvet and colleagues, who disagree with our conclusion that prolonging triple therapy is unlikely to be a clinically useful strategy.
One of the aims of our meta-analysis was to verify whether current European and U.S. recommendations (1, 2) that support 14 days as the duration of choice reflect the available data. Undoubtedly, increasing the duration of treatment from 7 to 14 days will statistically significantly increase the eradication rate by 5% (95% CI, 2% to 8%); however, this improvement is substantially lower than what was previously accepted (12%) (3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only